Atrial Fibrillation General Registry

Overview

Given the advances in Atrial Fibrillation (AF) management and the availability of new European Society of Cardiology (ESC) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of AF in the member ESC countries. It is now nearly 10 years since the last European registry of AF management was undertaken (as part of the ESC Euro Heart Survey programme), and a new registry was needed.

Full Title of Study: “Atrial Fibrillation General Long Term Registry”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2016

Detailed Description

Given the advances in Atrial Fibrillation (AF) management and the availability of new European Society of Cardiology (ESC) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of AF in the member ESC countries. It is now nearly 10 years since the last European registry of AF management was undertaken (as part of the ESC Euro Heart Survey programme), and a new registry was needed.

New guidelines on the management of AF have recently been published by the ESC, but it remains unclear how often clinicians adhere to them. Since the last Euro Heart survey, a change in management strategy has necessitated an update on prevalent management practices in AF. This is influenced by clinical availability of catheter ablation as a routine procedure and new antiarrhythmic drugs, and also by developments in stroke thromboprophylaxis and medical therapy options. Under the EURObservational Research Programme (EORP), an AF ablation sentinel pilot registry was launched in 2010.

A survey of AF management under the EORP programme will enable a timely assessment of the uptake of the new ESC guidelines, allow monitoring of implementation and uptake of catheter ablation, new antithrombotic drugs and new antiarrhythmic agents, and will inform about outcomes related to guideline-adherent management of AF.

Clinical Trial Outcome Measures

Primary Measures

  • vital status
    • Time Frame: Baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Patients will be officially enrolled in the study only if ECG diagnosis of AF has been made.
  • The qualifying episode of AF should have occurred within one year before the date of baseline.
  • AF is the primary or secondary diagnosis, i.e. the current admission / visit may be due to other reasons.
  • Patients need not be in AF at the time of enrolment.
  • Signed Patient Inform Consent if applicable.

Exclusion Criteria

  • No ECG/Holter with AF recorded.
  • Only atrial flutter recorded.
  • The qualifying episode of AF occurred more than one year before the date of baseline.
  • Age <18 years.
  • Patients are already included in the ESC Atrial Fibrillation Long-Term registry if your centre was enrolled in the Pilot phase.
  • Patients who are currently or are planned to be taking part in a cardiac clinical trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Society of Cardiology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gregory Lip, MD, Study Chair, European Society of Cardiology
  • Overall Contact(s)
    • Thierry Ferreira, MSc, 33 (0)4 89 87 20 44, tferreira@escardio.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.